A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study

Status

Not yet recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516511-24-00

Enrollment

136

Registered

2024-09-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic myeloid leukaemia

Brief summary

The primary study outcome is the proportion of patients with treatment failure at 12 months after first dose reduction.

Interventions

DRUGIMATINIB

DRUGPONATINIB

DRUGBOSUTINIB

DRUGNILOTINIB

DRUGDASATINIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary study outcome is the proportion of patients with treatment failure at 12 months after first dose reduction.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026